Sun H Kim1, Irwin G Brodsky2, Ranee Chatterjee3, Sangeeta R Kashyap4, William C Knowler5, Emilia Liao6, Jason Nelson7, Richard Pratley8, Neda Rasouli9, Ellen M Vickery10, Mark Sarnak11, Anastassios G Pittas10. 1. Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, California sunhkim@stanford.edu. 2. Endocrinology and Diabetes Center, Maine Medical Center, and Maine Medical Center Research Institute, Scarborough, Maine. 3. Department of Medicine, Duke University, Durham, North Carolina. 4. Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, Ohio. 5. Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona. 6. Division of Endocrinology and Metabolism, Northwell Health Lenox Hill Hospital, New York, New York. 7. Tufts Clinical and Translational Science Institute, Biostatistics, Epidemiology, and Research Design Center, Tufts Medical Center, Boston, Massachusetts. 8. AdventHealth Translational Research Institute, Orlando, Florida. 9. Division of Endocrinology, Metabolism and Diabetes, University of Colorado, School of Medicine and Veterans Affairs Eastern Colorado Health Care System, Aurora, Colorado. 10. Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, Massachusetts. 11. Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: Low serum 25-hydroxyvitamin D (25[OH]D) concentration has been associated with higher levels of proteinuria and lower levels of eGFR in observational studies. In the Vitamin D and Type 2 Diabetes (D2d) study, we investigated the effect of vitamin D supplementation on kidney outcomes in a population with prediabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Overweight/obese adults with high risk for type 2 diabetes (defined by meeting two of three glycemic criteria for prediabetes) were randomized to vitamin D3 4000 IU per day versus placebo. Median duration of treatment was 2.9 years (interquartile range 2.0-3.5 years). Kidney outcomes included (1) worsening in Kidney Disease: Improving Global Outcomes (KDIGO ) risk score (low, moderate, high, very high) on two consecutive follow-up visits after the baseline visit and (2) mean changes in eGFR and urine albumin-to-creatinine ratio (UACR). RESULTS: Among 2166 participants (mean age 60 years, body mass index 32 kg/m2, serum 25(OH)D 28 ng/ml, eGFR 87 ml/min per 1.73 m2, UACR 11 mg/g, 79% with hypertension), 10% had moderate, high, or very high KDIGO risk score. Over a median follow-up of 2.9 years, there were 28 cases of KDIGO worsening in the vitamin D group and 30 in the placebo group (hazard ratio, 0.89; 95% confidence interval [95% CI], 0.52 to 1.52]). Mean difference in eGFR from baseline was -1.0 ml/min per 1.73 m2 (95% CI, -1.3 to -0.7) in the vitamin D group and -0.1 ml/min per 1.73 m2 (95% CI, -0.4 to 0.2) in the placebo group; between-group difference was -1.0 ml/min per 1.73 m2 (95% CI, -1.4 to -0.6). Mean difference in UACR was 2.7 mg/g (95% CI, 1.2 to 4.3) in the vitamin D group and 2.0 (95% CI, 0.5 to 3.6) in the placebo group; between-group difference was 0.7 mg/g (95% CI, -1.5 to 2.9). CONCLUSIONS: Among persons with prediabetes, who were not preselected on the basis of serum 25(OH)D concentration, vitamin D supplementation did not affect progression of KDIGO risk scores and did not have a meaningful effect on change in UACR or eGFR.
BACKGROUND AND OBJECTIVES: Low serum 25-hydroxyvitamin D (25[OH]D) concentration has been associated with higher levels of proteinuria and lower levels of eGFR in observational studies. In the Vitamin D and Type 2 Diabetes (D2d) study, we investigated the effect of vitamin D supplementation on kidney outcomes in a population with prediabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Overweight/obese adults with high risk for type 2 diabetes (defined by meeting two of three glycemic criteria for prediabetes) were randomized to vitamin D3 4000 IU per day versus placebo. Median duration of treatment was 2.9 years (interquartile range 2.0-3.5 years). Kidney outcomes included (1) worsening in Kidney Disease: Improving Global Outcomes (KDIGO ) risk score (low, moderate, high, very high) on two consecutive follow-up visits after the baseline visit and (2) mean changes in eGFR and urine albumin-to-creatinine ratio (UACR). RESULTS: Among 2166 participants (mean age 60 years, body mass index 32 kg/m2, serum 25(OH)D 28 ng/ml, eGFR 87 ml/min per 1.73 m2, UACR 11 mg/g, 79% with hypertension), 10% had moderate, high, or very high KDIGO risk score. Over a median follow-up of 2.9 years, there were 28 cases of KDIGO worsening in the vitamin D group and 30 in the placebo group (hazard ratio, 0.89; 95% confidence interval [95% CI], 0.52 to 1.52]). Mean difference in eGFR from baseline was -1.0 ml/min per 1.73 m2 (95% CI, -1.3 to -0.7) in the vitamin D group and -0.1 ml/min per 1.73 m2 (95% CI, -0.4 to 0.2) in the placebo group; between-group difference was -1.0 ml/min per 1.73 m2 (95% CI, -1.4 to -0.6). Mean difference in UACR was 2.7 mg/g (95% CI, 1.2 to 4.3) in the vitamin D group and 2.0 (95% CI, 0.5 to 3.6) in the placebo group; between-group difference was 0.7 mg/g (95% CI, -1.5 to 2.9). CONCLUSIONS: Among persons with prediabetes, who were not preselected on the basis of serum 25(OH)D concentration, vitamin D supplementation did not affect progression of KDIGO risk scores and did not have a meaningful effect on change in UACR or eGFR.
Authors: Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress Journal: Lancet Date: 2010-11-06 Impact factor: 79.321
Authors: Yan Chun Li; Guilin Qiao; Milan Uskokovic; Wei Xiang; Wei Zheng; Juan Kong Journal: J Steroid Biochem Mol Biol Date: 2004-05 Impact factor: 4.292
Authors: Ian H de Boer; Leila R Zelnick; John Ruzinski; Georgina Friedenberg; Julie Duszlak; Vadim Y Bubes; Andrew N Hoofnagle; Ravi Thadhani; Robert J Glynn; Julie E Buring; Howard D Sesso; JoAnn E Manson Journal: JAMA Date: 2019-11-19 Impact factor: 56.272
Authors: Erin S LeBlanc; Richard E Pratley; Bess Dawson-Hughes; Myrlene A Staten; Patricia R Sheehan; Michael R Lewis; Anne Peters; Sun H Kim; Ranee Chatterjee; Vanita R Aroda; Chhavi Chadha; Lisa M Neff; Irwin G Brodsky; Clifford Rosen; Cyrus V Desouza; John P Foreyt; Daniel S Hsia; Karen C Johnson; Philip Raskin; Sangeeta R Kashyap; Patrick O'Neil; Lawrence S Phillips; Neda Rasouli; Emilia P Liao; David C Robbins; Anastassios G Pittas Journal: Diabetes Care Date: 2018-06-25 Impact factor: 19.112
Authors: João Soares Felício; Hana Andrade de Rider Britto; Pedro Celeira Cortez; Fabrício de Souza Resende; Manuela Nascimento de Lemos; Lorena Vilhena de Moraes; Vitória Teixeira de Aquino; Fernanda de Souza Parente; Natércia Neves Marques de Queiroz; João Felício Abrahão Neto; Angélica Leite de Alcântara; Wanderson Maia da Silva; Norberto Jorge Kzan de Souza Neto; Pedro Paulo Freire Piani; Ícaro José Araújo de Souza; Lilian de Souza D'Albuquerque Silva; Maria Clara Neres Iunes de Oliveira; Nivin Mazen Said; Gabriela Nascimento de Lemos; Franciane Trindade Cunha de Melo; Daniela Lopes Gomes; Ana Carolina Contente Braga de Souza; Melissa de Sá Oliveira Dos Reis; Valéria Suênya Galvão Leal; Isabel Jane Campos Lobato; Karem Miléo Felício Journal: Front Endocrinol (Lausanne) Date: 2021-10-07 Impact factor: 5.555